Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments

Blood (2016) 128 (22): 117.

https://doi.org/10.1182/blood.V128.22.117.117

Published: 2016

Journal Articles

Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations

Blood (2015) 126 (23): 369.

https://doi.org/10.1182/blood.V126.23.369.369

Published: 2015

Journal Articles

The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM

Blood (2015) 126 (23): 372.

https://doi.org/10.1182/blood.V126.23.372.372

Published: 2015

Journal Articles

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

Blood (2015) 126 (23): 3181.

https://doi.org/10.1182/blood.V126.23.3181.3181

Published: 2015

Journal Articles

Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials

Sharmilan Thanendrarajan, MD, Caleb K. Stein, MS, Faith E Davies, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Christoph Heuck, MD, Carolina Schinke, MD, Sarah Waheed, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Niels Weinhold, PhD, Aasiya Matin, Pankaj Mathur, Meera Mohan, Muthukumar Radhakrishnan, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 3182.

https://doi.org/10.1182/blood.V126.23.3182.3182

Published: 2015

Journal Articles

Molecular Subtyping and Risk Stratification for the Classification of Myeloma

Caleb K. Stein, MS, Faith E Davies, MD, Christoph Heuck, MD, Niels Weinhold, PhD, Shweta S. Chavan, PhD, Brian A Walker, PhD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Martin F Kaiser, MD, Graham H Jackson, MD PhD, Pieter Sonneveld, MD PhD, Hartmut Goldschmidt, MD, Peter Leif Bergsagel, MD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 4173.

https://doi.org/10.1182/blood.V126.23.4173.4173

Published: 2015

Journal Articles

Specific Exosomal microRNA Are Differentially Expressed Between High and Low-Risk Myeloma Suggesting They Are Pathogenically Important

Bangzheng Chen, PhD, Gareth J Morgan, MDPhD, Bart Barlogie, MD PhD, Joshua Epstein, DSc

Blood (2015) 126 (23): 4189.

https://doi.org/10.1182/blood.V126.23.4189.4189

Published: 2015

Journal Articles

Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience

Meera Mohan, Rohan Samant, Larry J Suva, Corey O Montgomery, Daisy V. Alapat, MD, Roy Morello, Frits van Rhee, MD PhD, Sarah Waheed, MD, Sharmilan Thanendrarajan, MD, Carolina Schinke, MD, Christoph Heuck, MD, Yogesh Jethava, MD, Donald Johann, MD MS, Bart Barlogie, MD PhD, Faith E Davies, MD, Gareth J Morgan, MDPhD, Maurizio Zangari, MD

Blood (2015) 126 (23): 4193.

https://doi.org/10.1182/blood.V126.23.4193.4193

Published: 2015

Journal Articles

Stem Cell-like Characteristics of MM Plasma Cells Vary By ROS Levels: Implications for Targeted Therapy

Priyangi A Malaviarachchi, BS, Donald E Turner, BS, Caleb K. Stein, MS, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Sarah K. Johnson, PhD

Blood (2015) 126 (23): 1820.

https://doi.org/10.1182/blood.V126.23.1820.1820

Published: 2015

Journal Articles

Gene Expression Profiling of Extramedullary Disease-Related Toward Identification of a Terminal Disease Pathway in Multiple Myeloma

Sarah Waheed, MD, Hongwei Wang, Pingping Qu, PhD, Christoph Heuck, MD, Aasiya Matin, Yogesh Jethava, MB, MRCP, MD FRCPath, Frits van Rhee, MD PhD, Antje Hoering, Bart Barlogie, MD PhD, Faith E Davies, MD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1777.

https://doi.org/10.1182/blood.V126.23.1777.1777

Published: 2015

Journal Articles

Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM)

Sharmilan Thanendrarajan, MD, Daisy V. Alapat, MD, Maurizio Zangari, MD, Carolina Schinke, MD, Christoph Heuck, MD, Frits van Rhee, MD PhD, Adam Rosenthal, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Faith E Davies, MD, Gareth J Morgan, MDPhD, Bart Barlogie, MD PhD

Blood (2015) 126 (23): 1843.

https://doi.org/10.1182/blood.V126.23.1843.1843

Published: 2015

Journal Articles

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Sarah K. Johnson, PhD, Pingping Qu, PhD, Frits van Rhee, MD PhD, Yogesh Jethava, MB, MRCP, MD FRCPath, Caleb K. Stein, MS, Emily Hansen, Alan Mitchell, Maurizio Zangari, MD, Christoph Heuck, MD, Rashid Z Khan, MD, Xenofon Papanikolaou, MD, Faith E Davies, MD, Antje Hoering, PhD, John Crowley, PhD, Niels Weinhold, PhD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1806.

https://doi.org/10.1182/blood.V126.23.1806.1806

Published: 2015

Journal Articles

Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma

Blood (2015) 126 (23): 2979.

https://doi.org/10.1182/blood.V126.23.2979.2979

Published: 2015

Journal Articles

Deletion of TP53 (17p13) Is Associated with Poor Outcome for Newly Diagnosed High-Risk Multiple Myeloma

Erming Tian, PhD, Joshua Epstein, DSc, Pingping Qu, PhD, Christoph Heuck, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Antje Hoering, Jeffery Sawyer, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 2982.

https://doi.org/10.1182/blood.V126.23.2982.2982

Published: 2015

Journal Articles

Differential ICAM3 Gene Expression Correlates with Susceptibility to Natural Killer Cell-Mediated Lysis in Multiple Myeloma

Tarun K. Garg, PhD, Ricky D Edmondson, PhD, Shweta S. Chavan, PhD, Katie Stone, BS, Justin M Stivers, Jessica I Warden, Veronica Macleod, Charles M Skinner, Joshuah D Lingo, Amy D Greenway, Junaid Khan, Donald Johann, MD MS, Christoph Heuck, MD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD, Joshua Epstein, DSc, Frits van Rhee, MD PhD

Blood (2015) 126 (23): 2990.

https://doi.org/10.1182/blood.V126.23.2990.2990

Published: 2015

Journal Articles

Profound Impact of Sample Processing Delay on Gene Expression of Multiple Myeloma Plasma Cells

Tobias Meissner, Anja Seckinger, MD, Kari Hemminki, PhD, Uta Bertsch, MD, Asta Foersti, Mathias Haenel, MD, Jan Duering, Hans-Juergen Salwender, MD, Hartmut Goldschmidt, MD, Gareth J Morgan, MDPhD, Dirk Hose, MD, Niels Weinhold, PhD

Blood (2015) 126 (23): 2996.

https://doi.org/10.1182/blood.V126.23.2996.2996

Published: 2015

Journal Articles

Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines

Shmuel Yaccoby, Joshua Epstein, DSc, Pingping Qu, PhD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Christoph Heuck, MD, Faith E Davies, MD, Alan Mitchell, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1808.

https://doi.org/10.1182/blood.V126.23.1808.1808

Published: 2015

Journal Articles

Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Xenofon Papanikolaou, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Adam Rosenthal, Nathan Petty, MS, Maurizio Zangari, MD, Christoph Heuck, MD, Frits van Rhee, MD PhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Gareth J Morgan, MDPhD, Faith E Davies, MD, Bart Barlogie, MD PhD

Blood (2015) 126 (23): 5395.

https://doi.org/10.1182/blood.V126.23.5395.5395

Published: 2015

Journal Articles

Outcomes of Autologous Transplantation for Treatment-Related AML and MDS in Previously Treated Multiple Myeloma Patients (pts)

Shebli Atrash, Bart Barlogie, MD PhD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Sarah Waheed, MD, Clyde Bailey, Nathan Petty, MS, Christoph Heuck, MD, Gareth J Morgan, MDPhD, Yogesh Jethava, MD

Blood (2015) 126 (23): 1997.

https://doi.org/10.1182/blood.V126.23.1997.1997

Published: 2015

Journal Articles

High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance

Blood (2015) 126 (23): 20.

https://doi.org/10.1182/blood.V126.23.20.20

Published: 2015

NARROW

A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments

Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations

The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials

Molecular Subtyping and Risk Stratification for the Classification of Myeloma

Specific Exosomal microRNA Are Differentially Expressed Between High and Low-Risk Myeloma Suggesting They Are Pathogenically Important

Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience

Stem Cell-like Characteristics of MM Plasma Cells Vary By ROS Levels: Implications for Targeted Therapy

Gene Expression Profiling of Extramedullary Disease-Related Toward Identification of a Terminal Disease Pathway in Multiple Myeloma

Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM)

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma

Deletion of TP53 (17p13) Is Associated with Poor Outcome for Newly Diagnosed High-Risk Multiple Myeloma

Differential ICAM3 Gene Expression Correlates with Susceptibility to Natural Killer Cell-Mediated Lysis in Multiple Myeloma

Profound Impact of Sample Processing Delay on Gene Expression of Multiple Myeloma Plasma Cells

Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines

Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Outcomes of Autologous Transplantation for Treatment-Related AML and MDS in Previously Treated Multiple Myeloma Patients (pts)

High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only